Xiaoling Ling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaoling Ling has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Fei Su
The First Clinical Medical College of Lanzhou University, Lanzhou, People’s Republic of China
6 shared publicationsMiao Zhao
Lanzhou Univ, Clin Med Coll 1, 199 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China
5 shared publications- Tao Zhang
Department of Oncology, The First Hospital of Lanzhou University, Lanzhou 730000, China
3 shared publications Yi Xiao
The First Clinical Medical College of Lanzhou University, Lanzhou 730099, Gansu, PR China; Breast Surgery, The First Hospital of Lanzhou University, Lanzhou 730013, Gansu, PR China
3 shared publicationsYunfei Xiang
Lanzhou Univ, Clin Med Coll 1, 199 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China
3 shared publicationsChenhao Guo
Lanzhou Univ, Clin Med Coll 1, 199 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China
2 shared publications
Latest Publications
- Open Access
- 3 February 2026
- Published by MDPI AG in Current Oncology
- Vol. 33  (2) , 92
Trop2-Based Antibody–Drug Conjugates: Emerging Strategy and Progress in Triple-Negative Breast Cancer Therapy
Triple-negative breast cancer (TNBC) accounts for 15–20% of invasive breast cancers and represents a highly heterogeneous, aggressive subtype with poor prognosis and limited treatment options, necessitating the identification of novel therapeutic targets to improve clinical outcomes. Trophoblast cell-surface antigen 2 (Trop2), a calcium signal transducer, is frequently overexpressed in TNBC (approximately 88% of cases) while exhibiting minimal expression in normal tissues. Its overexpression is significantly associated with tumor invasion, metastasis, and unfavorable prognosis. Antibody–drug conjugates (ADCs) targeting Trop2 have demonstrated significant clinical potential. This article systematically reviews the clinical research progress of Trop2-targeted ADCs, aiming to provide evidence-based insights for improving the prognosis of TNBC patients.
- 3 February 2026
- Published by MDPI AG in Current Oncology
- Vol. 33  (2) , 92
Open AccessTrop2-Based Antibody–Drug Conjugates: Emerging Strategy and Progress in Triple-Negative Breast Cancer Therapy
Triple-negative breast cancer (TNBC) accounts for 15–20% of invasive breast cancers and represents a highly heterogeneous, aggressive subtype with poor prognosis and limited treatment options, necessitating the identification of novel therapeutic targets to improve clinical outcomes. Trophoblast cell-surface antigen 2 (Trop2), a calcium signal transducer, is frequently overexpressed in TNBC (approximately 88% of cases) while exhibiting minimal expression in normal tissues. Its overexpression is significantly associated with tumor invasion, metastasis, and unfavorable prognosis. Antibody–drug conjugates (ADCs) targeting Trop2 have demonstrated significant clinical potential. This article systematically reviews the clinical research progress of Trop2-targeted ADCs, aiming to provide evidence-based insights for improving the prognosis of TNBC patients.
- 10 January 2026
- Published by Springer Nature in Apoptosis
- Vol. 31  (1) , 35
LncRNA PVT1 drives macrophage polarization and triple-negative breast cancer progression via PPARγ-mediated transcriptional activation
Triple-negative breast cancer (TNBC) is a clinically aggressive subtype with limited therapeutic strategies. Although long non-coding RNAs (lncRNAs) are increasingly linked to tumor progression, their regulatory role in macrophage polarization during TNBC remains unclear. This study investigates the molecular interplay between lncRNA PVT1 and PPARγ in driving macrophage reprogramming during TNBC progression. Utilizing an orthotopic TNBC mouse model, single-cell RNA sequencing (scRNA-seq) identified nine distinct cell types, with pseudotime trajectory analysis revealing macrophage accumulation in advanced tumor stages. Reannotation of macrophages highlighted M2-like polarization dominance during TNBC development. Bulk sequencing of TNBC macrophages and integrated GEO/TCGA analyses identified PPARγ as a key regulator and PVT1 as a differentially expressed lncRNA in TNBC versus normal tissues. In vitro experiments with THP-1/U937 macrophages demonstrated that PVT1 knockdown or PPARγ modulation altered macrophage polarization, subsequently affecting MDA-MB-231 and MCF-7 breast cancer cell proliferation and invasion. Mechanistically, RNA/DNA pulldown and luciferase assays confirmed that PVT1 recruits NOP56 and E2F1 to form a transcriptional complex, enhancing E2F1-driven PPARγ expression. In vivo, orthotopic tumors generated from PVT1-silenced THP-1/MDA-MB-231 cell mixtures exhibited suppressed growth, increased M1-like macrophages, and elevated apoptosis (TUNEL assay), whereas PPARγ overexpression accelerated tumor progression with M2-dominant infiltration (flow cytometry). These findings establish lncRNA PVT1 as a critical epigenetic scaffold coordinating NOP56-E2F1-PPARγ signaling to polarize macrophages toward a pro-tumorigenic M2 phenotype, thereby fueling TNBC aggressiveness. This study unveils novel therapeutic targets for TNBC by disrupting the PVT1-PPARγ axis to rebalance macrophage dynamics and induce tumor-suppressive immunity.
- 10 January 2026
- Published by Springer Nature in Apoptosis
- Vol. 31  (1) , 35
LncRNA PVT1 drives macrophage polarization and triple-negative breast cancer progression via PPARγ-mediated transcriptional activation
Triple-negative breast cancer (TNBC) is a clinically aggressive subtype with limited therapeutic strategies. Although long non-coding RNAs (lncRNAs) are increasingly linked to tumor progression, their regulatory role in macrophage polarization during TNBC remains unclear. This study investigates the molecular interplay between lncRNA PVT1 and PPARγ in driving macrophage reprogramming during TNBC progression. Utilizing an orthotopic TNBC mouse model, single-cell RNA sequencing (scRNA-seq) identified nine distinct cell types, with pseudotime trajectory analysis revealing macrophage accumulation in advanced tumor stages. Reannotation of macrophages highlighted M2-like polarization dominance during TNBC development. Bulk sequencing of TNBC macrophages and integrated GEO/TCGA analyses identified PPARγ as a key regulator and PVT1 as a differentially expressed lncRNA in TNBC versus normal tissues. In vitro experiments with THP-1/U937 macrophages demonstrated that PVT1 knockdown or PPARγ modulation altered macrophage polarization, subsequently affecting MDA-MB-231 and MCF-7 breast cancer cell proliferation and invasion. Mechanistically, RNA/DNA pulldown and luciferase assays confirmed that PVT1 recruits NOP56 and E2F1 to form a transcriptional complex, enhancing E2F1-driven PPARγ expression. In vivo, orthotopic tumors generated from PVT1-silenced THP-1/MDA-MB-231 cell mixtures exhibited suppressed growth, increased M1-like macrophages, and elevated apoptosis (TUNEL assay), whereas PPARγ overexpression accelerated tumor progression with M2-dominant infiltration (flow cytometry). These findings establish lncRNA PVT1 as a critical epigenetic scaffold coordinating NOP56-E2F1-PPARγ signaling to polarize macrophages toward a pro-tumorigenic M2 phenotype, thereby fueling TNBC aggressiveness. This study unveils novel therapeutic targets for TNBC by disrupting the PVT1-PPARγ axis to rebalance macrophage dynamics and induce tumor-suppressive immunity.
- Open Access
- 25 January 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51  (1) , 1-13
TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress
Increasing evidence suggests that key cancer-causing driver genes continue to exert a sustained influence on the tumor microenvironment (TME), highlighting the importance of immunotherapeutic targeting of gene mutations in governing tumor progression. TP53 is a prominent tumor suppressor that encodes the p53 protein, which controls the initiation and progression of different tumor types. Wild-type p53 maintains cell homeostasis and genomic instability through complex pathways, and mutant p53 (Mut p53) promotes tumor occurrence and development by regulating the TME. To date, it has been wildly considered that TP53 is able to mediate tumor immune escape. Herein, we summarized the relationship between TP53 gene and tumors, discussed the mechanism of Mut p53 mediated tumor immune escape, and summarized the progress of applying p53 protein in immunotherapy. This study will provide a basic basis for further exploration of therapeutic strategies targeting p53 protein.
- 25 January 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51  (1) , 1-13
Open AccessTP53 to mediate immune escape in tumor microenvironment: an overview of the research progress
Increasing evidence suggests that key cancer-causing driver genes continue to exert a sustained influence on the tumor microenvironment (TME), highlighting the importance of immunotherapeutic targeting of gene mutations in governing tumor progression. TP53 is a prominent tumor suppressor that encodes the p53 protein, which controls the initiation and progression of different tumor types. Wild-type p53 maintains cell homeostasis and genomic instability through complex pathways, and mutant p53 (Mut p53) promotes tumor occurrence and development by regulating the TME. To date, it has been wildly considered that TP53 is able to mediate tumor immune escape. Herein, we summarized the relationship between TP53 gene and tumors, discussed the mechanism of Mut p53 mediated tumor immune escape, and summarized the progress of applying p53 protein in immunotherapy. This study will provide a basic basis for further exploration of therapeutic strategies targeting p53 protein.
- Open Access
- 2 December 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47  (2) , 1321-1323
Double primary carcinomas of breast and duodenum with liver metastasis: A rare case report
- 2 December 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47  (2) , 1321-1323
Open AccessDouble primary carcinomas of breast and duodenum with liver metastasis: A rare case report
- 18 October 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 218, 115864
USP10 promotes the progression of triple-negative breast cancer by enhancing the stability of TCF4 protein
- 18 October 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 218, 115864
USP10 promotes the progression of triple-negative breast cancer by enhancing the stability of TCF4 protein
- Open Access
- 18 August 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46  (12) , 5538-5539
A case report of breast cancer with rare adrenal metastasis
- 18 August 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46  (12) , 5538-5539
Open AccessA case report of breast cancer with rare adrenal metastasis
- Open Access
- 2 August 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46  (11) , 5349-5350
A case of thyroid angiosarcoma
- 2 August 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46  (11) , 5349-5350
Open AccessA case of thyroid angiosarcoma
- Open Access
- 16 March 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46  (8) , 3252-3254
Nomograms prediction for young and middle-aged patients (aged under 50) with metastatic cervical cancer: Based on SEER database
- 16 March 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46  (8) , 3252-3254
Open AccessNomograms prediction for young and middle-aged patients (aged under 50) with metastatic cervical cancer: Based on SEER database
- Open Access
- 6 February 2023
- Published by Wiley
Clinical Characteristics, Risk Classification System, and Web-Based Nomograms for Young and Middle-Aged Patients (Aged Under 50) with Metastatic Cervical Cancer: Based on Seer Database
Background: Currently, there is a lack of systematic research on the prognostic variables of metastatic cervical cancer (mCEC) among young and middle-aged females. Therefore, this research is purposed to identify the independent prognostic markers in mCEC patients (< 50 years of age) and to develop the nomograms applicable to predict their prognosis. Materials and Methods: The data on patients pathologically proven to have cervical cancer between 2004 and 2015 were collected from the American detection, epidemiology, and results (SEER) database. Then, univariate and multivariate cox analyses were conducted to determine independent prognostic variables. On this basis, nomograms were constructed to predict the 12-, 24-, and 36-month overall survival (OS) of mCEC patients aged under 50. The model was evaluated for predictive accuracy, discriminant ability, and clinical value through the receiver operating characteristic curve, the calibration curve and the decision-making curve analysis. Additionally, a survival calculator based on nomogram and network was developed. Results: A total of 616 mCEC patients aged under 50 were involved in the research. They were divided into a training set (419) and a validation set (176), at a ratio of 7:3. The independent predictive markers include race, tumour size, T stage, chemotherapy, radiotherapy, and surgery. According ot the analysis of the calibration curve, receiver operating characteristic curve, and decision curve plotted for both the training and validation cohorts, the NOMOGRAMS was highly discriminative and applicable clinically. The AUC value at 12, 24, and 36 months was 0.741, 0.739, and 0.731 in the training set, and 0.760, 0.695, and 0.696 in the validation set, respectively. The nomograms proposed in this paper can be accessed via the link: [https://shubei11.shinyapps.io/Youngcervicalnomogram/.](https://shubei11.shinyapps.io/Youngcervicalnomogram/.) In addition, a method novel risk categorization was developed to categorise all patients into three groups depending on their prognosis. Conclusions: In this study, a unique web-based nomogram is developed to estimate the risk of OS among the young and middle-aged mCEC patients (< 50), which would be beneficial for clinicians to personalise both survival evaluation and therapeutic treatment for patients.
- 6 February 2023
- Published by Wiley
Open AccessClinical Characteristics, Risk Classification System, and Web-Based Nomograms for Young and Middle-Aged Patients (Aged Under 50) with Metastatic Cervical Cancer: Based on Seer Database
Background: Currently, there is a lack of systematic research on the prognostic variables of metastatic cervical cancer (mCEC) among young and middle-aged females. Therefore, this research is purposed to identify the independent prognostic markers in mCEC patients (< 50 years of age) and to develop the nomograms applicable to predict their prognosis. Materials and Methods: The data on patients pathologically proven to have cervical cancer between 2004 and 2015 were collected from the American detection, epidemiology, and results (SEER) database. Then, univariate and multivariate cox analyses were conducted to determine independent prognostic variables. On this basis, nomograms were constructed to predict the 12-, 24-, and 36-month overall survival (OS) of mCEC patients aged under 50. The model was evaluated for predictive accuracy, discriminant ability, and clinical value through the receiver operating characteristic curve, the calibration curve and the decision-making curve analysis. Additionally, a survival calculator based on nomogram and network was developed. Results: A total of 616 mCEC patients aged under 50 were involved in the research. They were divided into a training set (419) and a validation set (176), at a ratio of 7:3. The independent predictive markers include race, tumour size, T stage, chemotherapy, radiotherapy, and surgery. According ot the analysis of the calibration curve, receiver operating characteristic curve, and decision curve plotted for both the training and validation cohorts, the NOMOGRAMS was highly discriminative and applicable clinically. The AUC value at 12, 24, and 36 months was 0.741, 0.739, and 0.731 in the training set, and 0.760, 0.695, and 0.696 in the validation set, respectively. The nomograms proposed in this paper can be accessed via the link: [https://shubei11.shinyapps.io/Youngcervicalnomogram/.](https://shubei11.shinyapps.io/Youngcervicalnomogram/.) In addition, a method novel risk categorization was developed to categorise all patients into three groups depending on their prognosis. Conclusions: In this study, a unique web-based nomogram is developed to estimate the risk of OS among the young and middle-aged mCEC patients (< 50), which would be beneficial for clinicians to personalise both survival evaluation and therapeutic treatment for patients.
- Open Access
- 4 February 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46  (6) , 2587-2589
Male small-cell lung cancer with breast mass as the first manifestation: A rare case report
- 4 February 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46  (6) , 2587-2589
Open AccessMale small-cell lung cancer with breast mass as the first manifestation: A rare case report